AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Dapagliflozin/metformin XR FDC 5/500 mgDrug: Dapagliflozin/metformin XR FDC 10/1000 mg
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT04856007
- Locations
- 🇨🇳
Research Site, Suzhou, China
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
Completed
- Conditions
- Carcinoma, Small Cell
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT04854590
- Locations
- 🇯🇵
Research Site, Wakayama, Japan
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
Phase 3
Completed
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Other: Placebo
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 416
- Registration Number
- NCT04851964
- Locations
- 🇬🇧
Research Site, Stockport, United Kingdom
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
Phase 3
Terminated
- Conditions
- Hyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (SZC)Drug: SZC Placebo
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2690
- Registration Number
- NCT04847232
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1006361
- Registration Number
- NCT04847531
- Locations
- 🇬🇧
Research Site, London, Greater London, United Kingdom
Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults
Phase 1
Completed
- Conditions
- Evaluate PK Profile
- Interventions
- Biological: nirsevimabOther: Placebo
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT04840849
- Locations
- 🇨🇳
Research Site, Shanghai, China
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT04836975
- Locations
- 🇸🇦
Research Site, Riyadh, Saudi Arabia
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
Recruiting
- Conditions
- Ovarian Cancer
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT04830709
- Locations
- 🇩🇪
Research Site, Wuppertal, Germany
A Study of AZD8233 in Participants With Dyslipidemia.
Phase 1
Completed
- Conditions
- Dyslipidemia
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 87
- Registration Number
- NCT04823611
- Locations
- 🇯🇵
Research Site, Suita-shi, Japan
AZD9833 China PK Study
Phase 1
Completed
- Conditions
- ER+, HER2-, Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT04818632
- Locations
- 🇨🇳
Research Site, Wuhan, China
© Copyright 2025. All Rights Reserved by MedPath